Presentation is loading. Please wait.

Presentation is loading. Please wait.

Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris.

Published byAmy Armstrong Modified over 9 years ago

Similar presentations

Presentation on theme: "Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris."— Presentation transcript:

1 Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

2 Disclosure Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

3 Slide 3 Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

4 ICON7/AGO-OVAR 11 Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

5 ICON7/AGO-OVAR 11 PFS and OS Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

6 ICON7/AGO-OVAR 11 PFS and OS High risk group suboptimal stage III and stage IV Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

7 Molecular Classification of HGS Ovarian Cancer Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

8 Slide 8 Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

9 Slide 9 Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

10 Slide 10 Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

11 Slide 11 Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

12 Slide 12 Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

13 PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort Overall (n=359) Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

14 PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort High risk for progression (n=119) Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

15 PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort Proliferative Subtype (n=96) Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

16 PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort Mesenchymal Subtype (n=68) Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

17 PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort Differentiated Subtype (n=73) Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

18 PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort Immunoreactive Subtype (n=122) Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

19 Slide 19 Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

20 PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort Proliferative Subtype HGS (n=63) Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

21 PFS and OS AGO OVAR 11/ICON7 DASL Study Cohort Mesenchymal Subtype HGS (n=43) Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

22 Summary Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

23 Conclusion Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

24 Acknowledgements Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

25 Summary Presented By Boris Winterhoff at 2014 ASCO Annual Meeting

Download ppt "Bevacizumab may Differentially Improve Survival for Patients with the Proliferative and Mesenchymal Molecular Subtype of Ovarian Cancer Presented By Boris."

Similar presentations

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.

Slide 1 Presented By Susan Chang at 2014 ASCO Annual Meeting.
Presented By Anthony Cmelak at 2014 ASCO Annual Meeting

Presented By Anthony Cmelak at 2014 ASCO Annual Meeting
Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.

Lung Cancer: What’s New and What’s Old? Presented By Leora Horn at 2014 ASCO Annual Meeting.
Presented By Raymond Huang at 2014 ASCO Annual Meeting

Presented By Raymond Huang at 2014 ASCO Annual Meeting
Hazard Ratio 0.62 (0.41-0.94) P =.024 Larynx and Hypopharynx Overall Survival 166 Patients.

Hazard Ratio 0.62 ( ) P =.024 Larynx and Hypopharynx Overall Survival 166 Patients.
CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.

CALGB/SWOG 80405: Phase III trial of FOLFIRI or FOLFOX with Bevacizumab or Cetuximab for patients w/ KRAS wild type untreated metastatic adenocarcinoma.
Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent.

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.
Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.

Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.
GCIG Meeting 29th May 2009 The Implications of Primary Chemotherapy for Clinical Trials Iain McNeish Professor of Gynaecological Oncology Barts and the.

GCIG Meeting 29th May 2009 The Implications of Primary Chemotherapy for Clinical Trials Iain McNeish Professor of Gynaecological Oncology Barts and the.
Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.

Randomized Comparison of Ibrutinib Versus Ofatumumab in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results From the.
Colorectal cancer intrinsic subtypes are associated with prognosis, chemotherapy response, deficient mismatch repair and epithelial to mesenchymal transition.

Colorectal cancer intrinsic subtypes are associated with prognosis, chemotherapy response, deficient mismatch repair and epithelial to mesenchymal transition.
Highlights of the Day: LYMPHOMA Presented By Sonali Smith at 2014 ASCO Annual Meeting.

Highlights of the Day: LYMPHOMA Presented By Sonali Smith at 2014 ASCO Annual Meeting.
Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer.

Result of Interim Analysis of Overall Survival in the GCIG ICON7 Phase III Randomized Trial of Bevacizumab in Women with Newly Diagnosed Ovarian Cancer.
Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.

Efficacy and Safety of Continued Zoledronic Acid every 4 Weeks versus every 12 Weeks in Women with Bone Metastases from Breast Cancer: Results of the OPTIMIZE-2.
GOG0172: The Dings The recommended regimen is not feasible –Substitution of carboplatin for cisplatin –Reduce cisplatin from 100 mg/m 2 to 75 mg/m 2 –Change.

GOG0172: The Dings The recommended regimen is not feasible –Substitution of carboplatin for cisplatin –Reduce cisplatin from 100 mg/m 2 to 75 mg/m 2 –Change.
Www.OncologyEducation.ca Gemcitabine + Cisplatin +/- Bevacizumab as 1st-line Treatment of Advanced NSCLC: AVAiL Study Manegold PASCO 25:#7514, 2007/Ann.

Gemcitabine + Cisplatin +/- Bevacizumab as 1st-line Treatment of Advanced NSCLC: AVAiL Study Manegold PASCO 25:#7514, 2007/Ann.
Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS-936558, ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.

Efficacy and safety of anti-PD-1 antibody (Nivolumab: BMS , ONO-4538) in patients with platinum-resistant ovarian cancer Presented By Junzo Hamanishi.
A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.

A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid.
A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.

A Randomized Phase 2 Trial Comparing Efficacy of the Combination of the PARP-inhibitor Olaparib and the Anti-angiogenic Cediranib Against Olaparib Alone.

Similar presentations

Ads by Google